Galapagos NV (NASDAQ:GLPG) Forecasted to Post Q3 2024 Earnings of ($0.22) Per Share

Galapagos NV (NASDAQ:GLPG) – Equities research analysts at Leerink Partnrs issued their Q3 2024 earnings per share (EPS) estimates for Galapagos in a research report issued to clients and investors on Monday, September 9th. Leerink Partnrs analyst F. Khurshid forecasts that the biotechnology company will post earnings per share of ($0.22) for the quarter. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Galapagos’ current full-year earnings is $0.82 per share. Leerink Partnrs also issued estimates for Galapagos’ Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.09) EPS.

GLPG has been the topic of several other reports. Raymond James lowered Galapagos from an “outperform” rating to a “market perform” rating in a report on Friday, August 2nd. Leerink Partners initiated coverage on shares of Galapagos in a research note on Monday. They set a “market perform” rating and a $24.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and five have issued a hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $31.00.

Galapagos Stock Up 2.2 %

Shares of Galapagos stock opened at $28.99 on Wednesday. The company has a 50 day moving average price of $26.64 and a 200 day moving average price of $28.71. Galapagos has a 52 week low of $24.16 and a 52 week high of $42.46.

Hedge Funds Weigh In On Galapagos

Several institutional investors and hedge funds have recently modified their holdings of GLPG. Quadrant Capital Group LLC increased its holdings in Galapagos by 18.1% in the 4th quarter. Quadrant Capital Group LLC now owns 1,706 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 261 shares in the last quarter. Headlands Technologies LLC grew its position in shares of Galapagos by 56.7% in the second quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 446 shares during the period. Rhumbline Advisers increased its stake in shares of Galapagos by 21.6% during the second quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 814 shares in the last quarter. Signaturefd LLC increased its stake in shares of Galapagos by 48.1% during the second quarter. Signaturefd LLC now owns 3,872 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 1,258 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Galapagos by 66.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 3,769 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 1,504 shares during the last quarter. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.